Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Acute Coronary Syndrome | 31 | 2023 | 2184 | 5.510 |
Why?
|
Ticlopidine | 13 | 2022 | 732 | 2.590 |
Why?
|
Anticholesteremic Agents | 10 | 2024 | 970 | 2.380 |
Why?
|
Lipoprotein(a) | 7 | 2024 | 488 | 2.330 |
Why?
|
Myocardial Infarction | 36 | 2024 | 11504 | 2.180 |
Why?
|
Platelet Aggregation Inhibitors | 25 | 2024 | 2771 | 2.040 |
Why?
|
Benzaldehydes | 8 | 2018 | 59 | 1.710 |
Why?
|
Purinergic P2Y Receptor Antagonists | 5 | 2022 | 284 | 1.570 |
Why?
|
Atherosclerosis | 10 | 2024 | 3425 | 1.550 |
Why?
|
Oximes | 8 | 2018 | 305 | 1.530 |
Why?
|
Pyridines | 11 | 2021 | 2889 | 1.500 |
Why?
|
Hemorrhage | 12 | 2023 | 3461 | 1.260 |
Why?
|
Angina, Unstable | 5 | 2020 | 893 | 1.110 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 10 | 2023 | 3251 | 1.090 |
Why?
|
Heart Failure | 23 | 2023 | 11840 | 1.040 |
Why?
|
Cardiovascular Diseases | 21 | 2024 | 15648 | 1.040 |
Why?
|
Double-Blind Method | 24 | 2024 | 12433 | 0.990 |
Why?
|
Imines | 4 | 2012 | 26 | 0.970 |
Why?
|
Thiophenes | 5 | 2013 | 569 | 0.920 |
Why?
|
RNA, Small Interfering | 2 | 2024 | 3419 | 0.910 |
Why?
|
Cyclopropanes | 2 | 2016 | 437 | 0.890 |
Why?
|
Sex Characteristics | 5 | 2023 | 2643 | 0.880 |
Why?
|
Coronary Artery Disease | 14 | 2024 | 6545 | 0.870 |
Why?
|
Natriuretic Peptide, Brain | 11 | 2023 | 1736 | 0.860 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 3 | 2021 | 693 | 0.820 |
Why?
|
Stroke | 14 | 2024 | 9747 | 0.820 |
Why?
|
Guilt | 1 | 2022 | 92 | 0.750 |
Why?
|
Coronary Restenosis | 2 | 2021 | 396 | 0.730 |
Why?
|
Lactones | 3 | 2019 | 316 | 0.720 |
Why?
|
Early Termination of Clinical Trials | 1 | 2021 | 70 | 0.720 |
Why?
|
Women | 2 | 2020 | 226 | 0.710 |
Why?
|
Calgranulin A | 1 | 2021 | 80 | 0.710 |
Why?
|
Calgranulin B | 1 | 2021 | 87 | 0.700 |
Why?
|
1-Alkyl-2-acetylglycerophosphocholine Esterase | 5 | 2018 | 127 | 0.700 |
Why?
|
Phospholipases A | 2 | 2014 | 204 | 0.670 |
Why?
|
Judgment | 1 | 2022 | 270 | 0.660 |
Why?
|
Platelet Function Tests | 2 | 2021 | 275 | 0.640 |
Why?
|
Heptanoic Acids | 2 | 2014 | 344 | 0.610 |
Why?
|
Pravastatin | 2 | 2014 | 391 | 0.610 |
Why?
|
P-Selectin | 1 | 2021 | 597 | 0.610 |
Why?
|
Thrombolytic Therapy | 6 | 2013 | 2059 | 0.600 |
Why?
|
Piperazines | 5 | 2013 | 2546 | 0.600 |
Why?
|
Drug Therapy | 1 | 2021 | 504 | 0.580 |
Why?
|
Fatty Acid-Binding Proteins | 3 | 2013 | 291 | 0.580 |
Why?
|
Fatty Acids, Omega-3 | 3 | 2023 | 1396 | 0.570 |
Why?
|
Secondary Prevention | 7 | 2019 | 1472 | 0.570 |
Why?
|
Hypercholesterolemia | 2 | 2022 | 1149 | 0.560 |
Why?
|
Cholesterol, LDL | 9 | 2024 | 2393 | 0.560 |
Why?
|
Receptors, Thrombin | 3 | 2014 | 130 | 0.560 |
Why?
|
Cystatin C | 1 | 2018 | 272 | 0.550 |
Why?
|
Proton Pump Inhibitors | 3 | 2013 | 553 | 0.550 |
Why?
|
Drug-Eluting Stents | 2 | 2021 | 683 | 0.540 |
Why?
|
Thrombosis | 4 | 2024 | 2949 | 0.530 |
Why?
|
Glomerular Filtration Rate | 6 | 2022 | 2233 | 0.520 |
Why?
|
Glucosides | 1 | 2021 | 531 | 0.520 |
Why?
|
CD40 Ligand | 2 | 2021 | 528 | 0.510 |
Why?
|
Treatment Outcome | 36 | 2024 | 65180 | 0.500 |
Why?
|
Humans | 125 | 2024 | 765734 | 0.500 |
Why?
|
Diabetic Angiopathies | 3 | 2016 | 805 | 0.500 |
Why?
|
Peptide Fragments | 9 | 2023 | 5125 | 0.490 |
Why?
|
Death, Sudden, Cardiac | 3 | 2021 | 1567 | 0.480 |
Why?
|
Risk Assessment | 16 | 2021 | 24279 | 0.480 |
Why?
|
Sleep Disorders, Circadian Rhythm | 1 | 2017 | 197 | 0.480 |
Why?
|
Galectin 3 | 2 | 2016 | 237 | 0.470 |
Why?
|
Platelet Activation | 4 | 2016 | 645 | 0.460 |
Why?
|
Coronary Disease | 4 | 2018 | 5911 | 0.460 |
Why?
|
Pyrroles | 2 | 2014 | 1119 | 0.450 |
Why?
|
Adenosine Monophosphate | 1 | 2016 | 231 | 0.450 |
Why?
|
Aspirin | 5 | 2022 | 3135 | 0.450 |
Why?
|
Benzhydryl Compounds | 1 | 2021 | 939 | 0.450 |
Why?
|
Female | 82 | 2024 | 395961 | 0.440 |
Why?
|
Male | 76 | 2024 | 363585 | 0.440 |
Why?
|
Cardiovascular Agents | 2 | 2021 | 851 | 0.420 |
Why?
|
Blood Platelets | 6 | 2023 | 2463 | 0.420 |
Why?
|
Randomized Controlled Trials as Topic | 12 | 2021 | 10385 | 0.410 |
Why?
|
Middle Aged | 56 | 2024 | 222903 | 0.410 |
Why?
|
Aged | 53 | 2024 | 171050 | 0.410 |
Why?
|
Ischemia | 1 | 2021 | 1910 | 0.410 |
Why?
|
Risk Factors | 35 | 2024 | 74831 | 0.410 |
Why?
|
Blood Proteins | 2 | 2016 | 1188 | 0.400 |
Why?
|
Acetates | 1 | 2014 | 314 | 0.400 |
Why?
|
Fibroblast Growth Factors | 1 | 2018 | 871 | 0.390 |
Why?
|
Dyspnea | 8 | 2008 | 1352 | 0.390 |
Why?
|
Thiazoles | 2 | 2021 | 1529 | 0.390 |
Why?
|
Electrocardiography | 4 | 2021 | 6401 | 0.380 |
Why?
|
Phospholipases A2, Secretory | 1 | 2011 | 30 | 0.380 |
Why?
|
Angioplasty, Balloon, Coronary | 3 | 2009 | 1727 | 0.380 |
Why?
|
Communication Barriers | 1 | 2014 | 418 | 0.370 |
Why?
|
Women's Health | 2 | 2024 | 2083 | 0.360 |
Why?
|
Atrial Fibrillation | 6 | 2023 | 5188 | 0.350 |
Why?
|
Adenosine | 1 | 2015 | 806 | 0.350 |
Why?
|
Interleukin-18 | 1 | 2012 | 251 | 0.350 |
Why?
|
Calcium Channel Blockers | 1 | 2013 | 685 | 0.350 |
Why?
|
Myocardial Revascularization | 3 | 2016 | 793 | 0.340 |
Why?
|
Receptor, PAR-1 | 3 | 2019 | 109 | 0.340 |
Why?
|
Aryl Hydrocarbon Hydroxylases | 1 | 2011 | 246 | 0.330 |
Why?
|
Purinergic P2 Receptor Antagonists | 1 | 2009 | 67 | 0.320 |
Why?
|
Fibrinolytic Agents | 4 | 2024 | 2081 | 0.320 |
Why?
|
Oxytocin | 2 | 2024 | 404 | 0.320 |
Why?
|
Protein Kinase Inhibitors | 2 | 2016 | 5693 | 0.320 |
Why?
|
Inflammation Mediators | 1 | 2017 | 1885 | 0.310 |
Why?
|
Indoles | 2 | 2014 | 1832 | 0.300 |
Why?
|
Kidney Diseases | 1 | 2019 | 2097 | 0.300 |
Why?
|
Proportional Hazards Models | 8 | 2019 | 12509 | 0.280 |
Why?
|
Interleukin-6 | 1 | 2017 | 3229 | 0.280 |
Why?
|
Platelet Aggregation | 4 | 2017 | 769 | 0.280 |
Why?
|
Kaplan-Meier Estimate | 5 | 2017 | 6499 | 0.280 |
Why?
|
Dose-Response Relationship, Drug | 8 | 2024 | 10730 | 0.280 |
Why?
|
Warfarin | 1 | 2015 | 1494 | 0.260 |
Why?
|
Plaque, Atherosclerotic | 1 | 2017 | 1530 | 0.260 |
Why?
|
Stents | 4 | 2022 | 3213 | 0.250 |
Why?
|
Recurrence | 5 | 2018 | 8498 | 0.250 |
Why?
|
Administration, Intranasal | 2 | 2024 | 482 | 0.240 |
Why?
|
Creatinine | 4 | 2022 | 1915 | 0.240 |
Why?
|
Disease Management | 1 | 2016 | 2534 | 0.240 |
Why?
|
Genome-Wide Association Study | 10 | 2022 | 12800 | 0.240 |
Why?
|
Genetic Pleiotropy | 2 | 2016 | 182 | 0.240 |
Why?
|
Health Status Disparities | 2 | 2024 | 1880 | 0.230 |
Why?
|
Sleep Apnea, Obstructive | 1 | 2017 | 1899 | 0.230 |
Why?
|
Coronary Thrombosis | 2 | 2019 | 440 | 0.230 |
Why?
|
Sex Factors | 5 | 2021 | 10605 | 0.220 |
Why?
|
Renal Insufficiency | 2 | 2022 | 804 | 0.220 |
Why?
|
Prognosis | 13 | 2023 | 29899 | 0.220 |
Why?
|
Troponin T | 3 | 2016 | 785 | 0.220 |
Why?
|
Diabetes Mellitus | 2 | 2022 | 5891 | 0.220 |
Why?
|
Evidence-Based Medicine | 2 | 2015 | 3684 | 0.220 |
Why?
|
Drug Interactions | 3 | 2013 | 1416 | 0.200 |
Why?
|
Multivariate Analysis | 6 | 2017 | 12056 | 0.200 |
Why?
|
Subtilisins | 1 | 2022 | 80 | 0.200 |
Why?
|
N-Acetylgalactosaminyltransferases | 1 | 2022 | 63 | 0.200 |
Why?
|
Anticoagulants | 3 | 2024 | 4862 | 0.200 |
Why?
|
Diabetes Mellitus, Type 2 | 3 | 2021 | 12238 | 0.190 |
Why?
|
Acute Kidney Injury | 1 | 2014 | 1945 | 0.190 |
Why?
|
Sleep | 1 | 2017 | 4824 | 0.190 |
Why?
|
Venous Thrombosis | 2 | 2022 | 1327 | 0.190 |
Why?
|
Ceramides | 1 | 2022 | 201 | 0.180 |
Why?
|
Subtilisin | 1 | 2020 | 12 | 0.180 |
Why?
|
Pulmonary Embolism | 3 | 2023 | 2598 | 0.170 |
Why?
|
Aortic Valve Stenosis | 2 | 2024 | 2023 | 0.170 |
Why?
|
Antibodies, Monoclonal | 4 | 2024 | 9245 | 0.160 |
Why?
|
Drug Therapy, Combination | 5 | 2022 | 6307 | 0.160 |
Why?
|
Myocardium | 1 | 2012 | 4763 | 0.160 |
Why?
|
Growth Differentiation Factor 15 | 2 | 2023 | 198 | 0.160 |
Why?
|
Databases, Factual | 1 | 2015 | 8062 | 0.160 |
Why?
|
Obesity | 4 | 2024 | 13079 | 0.160 |
Why?
|
Serine Proteinase Inhibitors | 1 | 2020 | 174 | 0.150 |
Why?
|
Scavenger Receptors, Class B | 1 | 2018 | 83 | 0.150 |
Why?
|
Odds Ratio | 4 | 2017 | 9647 | 0.150 |
Why?
|
Hospitalization | 5 | 2018 | 10806 | 0.150 |
Why?
|
Incidence | 5 | 2021 | 21478 | 0.150 |
Why?
|
Phospholipids | 1 | 2022 | 776 | 0.150 |
Why?
|
Venous Thromboembolism | 2 | 2022 | 1882 | 0.150 |
Why?
|
Interleukin-13 Receptor alpha1 Subunit | 1 | 2017 | 23 | 0.150 |
Why?
|
Postoperative Complications | 1 | 2020 | 15749 | 0.140 |
Why?
|
Thromboembolism | 1 | 2024 | 1003 | 0.140 |
Why?
|
Genetic Variation | 3 | 2017 | 6607 | 0.140 |
Why?
|
Drug Administration Schedule | 2 | 2016 | 4850 | 0.140 |
Why?
|
Fatty Acids | 1 | 2024 | 1806 | 0.130 |
Why?
|
Renal Insufficiency, Chronic | 2 | 2022 | 2309 | 0.130 |
Why?
|
Patients | 1 | 2023 | 910 | 0.130 |
Why?
|
Osteoporosis, Postmenopausal | 1 | 2019 | 399 | 0.130 |
Why?
|
Quantitative Trait, Heritable | 1 | 2019 | 541 | 0.130 |
Why?
|
Adrenomedullin | 1 | 2016 | 85 | 0.130 |
Why?
|
C-Reactive Protein | 4 | 2016 | 3850 | 0.130 |
Why?
|
Models, Biological | 1 | 2012 | 9441 | 0.130 |
Why?
|
Pregnancy-Associated Plasma Protein-A | 1 | 2016 | 59 | 0.130 |
Why?
|
Withholding Treatment | 1 | 2020 | 621 | 0.130 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2019 | 878 | 0.120 |
Why?
|
Placebos | 2 | 2021 | 1659 | 0.120 |
Why?
|
Diabetic Nephropathies | 1 | 2022 | 969 | 0.120 |
Why?
|
Neutrophils | 1 | 2008 | 3772 | 0.120 |
Why?
|
Troponin I | 3 | 2013 | 655 | 0.120 |
Why?
|
Atrial Natriuretic Factor | 1 | 2016 | 348 | 0.120 |
Why?
|
Placebo Effect | 1 | 2019 | 514 | 0.120 |
Why?
|
Drug Monitoring | 1 | 2021 | 961 | 0.120 |
Why?
|
Risk | 3 | 2019 | 9592 | 0.120 |
Why?
|
Energy Intake | 2 | 2024 | 2141 | 0.120 |
Why?
|
Glycopeptides | 1 | 2016 | 224 | 0.120 |
Why?
|
Myocardial Ischemia | 2 | 2016 | 2129 | 0.120 |
Why?
|
Biphenyl Compounds | 1 | 2019 | 1020 | 0.110 |
Why?
|
Simvastatin | 1 | 2017 | 345 | 0.110 |
Why?
|
Cardiology | 2 | 2024 | 1702 | 0.110 |
Why?
|
Immune System Diseases | 1 | 2016 | 251 | 0.110 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 2 | 2011 | 1514 | 0.110 |
Why?
|
Chi-Square Distribution | 2 | 2017 | 3432 | 0.110 |
Why?
|
Quantitative Trait Loci | 2 | 2019 | 2137 | 0.110 |
Why?
|
Chest Pain | 2 | 2013 | 1100 | 0.110 |
Why?
|
Clinical Trials as Topic | 5 | 2021 | 8038 | 0.110 |
Why?
|
Galectins | 1 | 2016 | 294 | 0.110 |
Why?
|
Aged, 80 and over | 10 | 2021 | 59459 | 0.100 |
Why?
|
Genetic Association Studies | 2 | 2019 | 2740 | 0.100 |
Why?
|
Peroxidase | 1 | 2016 | 605 | 0.100 |
Why?
|
Predictive Value of Tests | 6 | 2011 | 15390 | 0.100 |
Why?
|
Proprotein Convertases | 1 | 2013 | 95 | 0.100 |
Why?
|
Dyslipidemias | 1 | 2020 | 869 | 0.100 |
Why?
|
Time Factors | 6 | 2020 | 40066 | 0.100 |
Why?
|
Erythropoiesis | 1 | 2016 | 691 | 0.100 |
Why?
|
Bone Density Conservation Agents | 1 | 2019 | 791 | 0.100 |
Why?
|
Patient Participation | 1 | 2021 | 1455 | 0.100 |
Why?
|
Stroke Volume | 2 | 2006 | 5596 | 0.100 |
Why?
|
Protein Precursors | 1 | 2016 | 1134 | 0.100 |
Why?
|
ROC Curve | 4 | 2008 | 3618 | 0.100 |
Why?
|
Language | 1 | 2021 | 1549 | 0.090 |
Why?
|
Kidney | 3 | 2022 | 7066 | 0.090 |
Why?
|
Logistic Models | 4 | 2017 | 13261 | 0.090 |
Why?
|
Genetic Loci | 2 | 2022 | 2631 | 0.090 |
Why?
|
Clinical Enzyme Tests | 1 | 2011 | 114 | 0.090 |
Why?
|
Hypoglycemic Agents | 2 | 2021 | 3109 | 0.090 |
Why?
|
Energy Metabolism | 2 | 2024 | 2891 | 0.090 |
Why?
|
Polymorphism, Single Nucleotide | 3 | 2019 | 16041 | 0.090 |
Why?
|
Genetic Predisposition to Disease | 4 | 2024 | 18061 | 0.090 |
Why?
|
Analysis of Variance | 1 | 2018 | 6203 | 0.080 |
Why?
|
Data Mining | 1 | 2015 | 562 | 0.080 |
Why?
|
Treatment Failure | 1 | 2016 | 2653 | 0.080 |
Why?
|
Phospholipases A2 | 2 | 2007 | 197 | 0.080 |
Why?
|
Postoperative Hemorrhage | 1 | 2013 | 413 | 0.080 |
Why?
|
Adipose Tissue | 1 | 2021 | 3313 | 0.080 |
Why?
|
Cat Diseases | 1 | 2008 | 32 | 0.080 |
Why?
|
Receptors, Cell Surface | 2 | 2008 | 2817 | 0.080 |
Why?
|
Urinary Calculi | 1 | 2008 | 81 | 0.080 |
Why?
|
Oxalates | 1 | 2008 | 99 | 0.080 |
Why?
|
Bifidobacterium | 1 | 2008 | 99 | 0.070 |
Why?
|
Leukocytes | 1 | 2016 | 2027 | 0.070 |
Why?
|
Serine Endopeptidases | 1 | 2013 | 1024 | 0.070 |
Why?
|
Dog Diseases | 1 | 2008 | 142 | 0.070 |
Why?
|
Liver Cirrhosis | 1 | 2018 | 1959 | 0.070 |
Why?
|
Research Design | 2 | 2015 | 6207 | 0.070 |
Why?
|
Cardiomyopathies | 1 | 2020 | 2067 | 0.070 |
Why?
|
Acute Disease | 3 | 2007 | 7232 | 0.070 |
Why?
|
Diagnostic Techniques, Cardiovascular | 1 | 2008 | 153 | 0.070 |
Why?
|
Cognition | 1 | 2024 | 7048 | 0.070 |
Why?
|
Disease-Free Survival | 1 | 2017 | 6832 | 0.070 |
Why?
|
Lactobacillus | 1 | 2008 | 213 | 0.070 |
Why?
|
Necrosis | 1 | 2011 | 1613 | 0.070 |
Why?
|
Erythrocytes | 1 | 2016 | 2393 | 0.070 |
Why?
|
Ventricular Function, Left | 1 | 2020 | 3930 | 0.070 |
Why?
|
Liver | 1 | 2022 | 7559 | 0.070 |
Why?
|
Area Under Curve | 2 | 2008 | 1639 | 0.070 |
Why?
|
Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2009 | 580 | 0.070 |
Why?
|
Diuretics | 1 | 2009 | 613 | 0.070 |
Why?
|
Epidemiologic Methods | 2 | 2008 | 1325 | 0.070 |
Why?
|
Cerebrovascular Disorders | 1 | 2013 | 1470 | 0.060 |
Why?
|
Syndrome | 2 | 2017 | 3268 | 0.060 |
Why?
|
Spironolactone | 1 | 2009 | 415 | 0.060 |
Why?
|
Propensity Score | 1 | 2013 | 1968 | 0.060 |
Why?
|
Glucose | 1 | 2017 | 4334 | 0.060 |
Why?
|
Coronary Angiography | 2 | 2008 | 4494 | 0.060 |
Why?
|
Survival Rate | 2 | 2018 | 12787 | 0.060 |
Why?
|
Genotype | 2 | 2016 | 13024 | 0.060 |
Why?
|
Healthcare Disparities | 2 | 2024 | 3412 | 0.060 |
Why?
|
Probiotics | 1 | 2008 | 387 | 0.060 |
Why?
|
Follow-Up Studies | 5 | 2014 | 39180 | 0.060 |
Why?
|
Enzymes | 1 | 2006 | 254 | 0.060 |
Why?
|
Pyrrolidines | 1 | 2006 | 337 | 0.060 |
Why?
|
Leukocyte Count | 1 | 2008 | 1602 | 0.060 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2009 | 1238 | 0.060 |
Why?
|
Data Interpretation, Statistical | 1 | 2013 | 2685 | 0.050 |
Why?
|
Alanine | 1 | 2006 | 613 | 0.050 |
Why?
|
Emergency Service, Hospital | 6 | 2008 | 7875 | 0.050 |
Why?
|
Reproducibility of Results | 1 | 2021 | 20120 | 0.050 |
Why?
|
Adult | 9 | 2024 | 222974 | 0.050 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2007 | 698 | 0.050 |
Why?
|
Liver Diseases | 1 | 2011 | 1303 | 0.050 |
Why?
|
United States | 5 | 2024 | 72898 | 0.050 |
Why?
|
Heart Valve Prosthesis Implantation | 1 | 2013 | 1566 | 0.050 |
Why?
|
Sensitivity and Specificity | 2 | 2007 | 14637 | 0.050 |
Why?
|
Infusions, Subcutaneous | 1 | 2021 | 43 | 0.050 |
Why?
|
Inflammation | 2 | 2012 | 10846 | 0.050 |
Why?
|
Weight Loss | 2 | 2024 | 2710 | 0.050 |
Why?
|
Age Factors | 2 | 2017 | 18375 | 0.050 |
Why?
|
Prospective Studies | 6 | 2024 | 54795 | 0.050 |
Why?
|
Disease Progression | 1 | 2017 | 13614 | 0.040 |
Why?
|
Antihypertensive Agents | 1 | 2009 | 2033 | 0.040 |
Why?
|
Gene Frequency | 2 | 2017 | 3623 | 0.040 |
Why?
|
Body Mass Index | 1 | 2017 | 13044 | 0.040 |
Why?
|
Eicosapentaenoic Acid | 1 | 2023 | 565 | 0.040 |
Why?
|
Uromodulin | 1 | 2019 | 49 | 0.040 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2020 | 372 | 0.040 |
Why?
|
Protein Disulfide-Isomerases | 1 | 2020 | 209 | 0.040 |
Why?
|
Niacin | 1 | 2019 | 116 | 0.040 |
Why?
|
Canada | 1 | 2024 | 2119 | 0.040 |
Why?
|
Lung Diseases | 1 | 2008 | 1940 | 0.040 |
Why?
|
AMP-Activated Protein Kinases | 1 | 2020 | 594 | 0.030 |
Why?
|
Inheritance Patterns | 1 | 2019 | 345 | 0.030 |
Why?
|
Child, Preschool | 1 | 2020 | 42468 | 0.030 |
Why?
|
Kidney Function Tests | 1 | 2019 | 683 | 0.030 |
Why?
|
Longitudinal Studies | 2 | 2024 | 14745 | 0.030 |
Why?
|
Docosahexaenoic Acids | 1 | 2023 | 916 | 0.030 |
Why?
|
Carbohydrate Metabolism | 1 | 2017 | 261 | 0.030 |
Why?
|
Allelic Imbalance | 1 | 2016 | 77 | 0.030 |
Why?
|
Animals | 7 | 2022 | 168731 | 0.030 |
Why?
|
History, 20th Century | 1 | 2024 | 2761 | 0.030 |
Why?
|
Erythrocyte Indices | 1 | 2016 | 144 | 0.030 |
Why?
|
Algorithms | 1 | 2016 | 14061 | 0.030 |
Why?
|
Blood Cell Count | 1 | 2016 | 404 | 0.030 |
Why?
|
Practice Guidelines as Topic | 1 | 2012 | 7424 | 0.030 |
Why?
|
Hematocrit | 1 | 2016 | 621 | 0.030 |
Why?
|
Osteoporotic Fractures | 1 | 2019 | 415 | 0.030 |
Why?
|
Microfilament Proteins | 1 | 2020 | 1130 | 0.030 |
Why?
|
Registries | 2 | 2022 | 8293 | 0.030 |
Why?
|
Body Composition | 1 | 2024 | 2441 | 0.030 |
Why?
|
Smoking | 1 | 2011 | 9077 | 0.030 |
Why?
|
Homozygote | 1 | 2019 | 1774 | 0.030 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2020 | 1151 | 0.030 |
Why?
|
Muscle Proteins | 1 | 2020 | 1160 | 0.030 |
Why?
|
Medicare | 2 | 2023 | 6821 | 0.030 |
Why?
|
Mendelian Randomization Analysis | 1 | 2020 | 1039 | 0.030 |
Why?
|
Neoplasms | 1 | 2023 | 22345 | 0.030 |
Why?
|
Pharmaceutical Preparations | 1 | 2022 | 1084 | 0.030 |
Why?
|
Platelet Count | 1 | 2016 | 782 | 0.030 |
Why?
|
Interleukin-4 | 1 | 2017 | 1162 | 0.030 |
Why?
|
Quality Control | 1 | 2016 | 835 | 0.030 |
Why?
|
Drug Resistance | 1 | 2019 | 1591 | 0.030 |
Why?
|
Survival Analysis | 1 | 2006 | 10069 | 0.030 |
Why?
|
Cross-Over Studies | 2 | 2011 | 2108 | 0.030 |
Why?
|
Periodicals as Topic | 1 | 2024 | 1462 | 0.030 |
Why?
|
Spinal Fractures | 1 | 2019 | 703 | 0.030 |
Why?
|
Internationality | 1 | 2018 | 1006 | 0.030 |
Why?
|
Europe | 1 | 2019 | 3423 | 0.030 |
Why?
|
Leadership | 1 | 2021 | 1392 | 0.020 |
Why?
|
Cohort Studies | 3 | 2018 | 41631 | 0.020 |
Why?
|
Triglycerides | 1 | 2019 | 2441 | 0.020 |
Why?
|
Cytochrome P-450 CYP1A2 | 1 | 2011 | 68 | 0.020 |
Why?
|
Hip Fractures | 1 | 2019 | 997 | 0.020 |
Why?
|
Chromosome Mapping | 1 | 2019 | 4618 | 0.020 |
Why?
|
Drosophila | 1 | 2017 | 1501 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2024 | 7835 | 0.020 |
Why?
|
Hemoglobins | 1 | 2016 | 1528 | 0.020 |
Why?
|
Critical Illness | 1 | 2022 | 2744 | 0.020 |
Why?
|
Risk Reduction Behavior | 1 | 2016 | 1123 | 0.020 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2020 | 2896 | 0.020 |
Why?
|
Recombinant Proteins | 1 | 2017 | 6492 | 0.020 |
Why?
|
Fractures, Bone | 1 | 2019 | 2040 | 0.020 |
Why?
|
Cats | 1 | 2008 | 972 | 0.020 |
Why?
|
Case-Control Studies | 2 | 2020 | 22224 | 0.020 |
Why?
|
Carrier Proteins | 1 | 2020 | 4912 | 0.020 |
Why?
|
Bone Density | 1 | 2019 | 3490 | 0.020 |
Why?
|
Blood Urea Nitrogen | 1 | 2006 | 189 | 0.020 |
Why?
|
Heart Murmurs | 1 | 2006 | 92 | 0.020 |
Why?
|
Genomics | 1 | 2021 | 5924 | 0.020 |
Why?
|
Mortality | 1 | 2016 | 2904 | 0.010 |
Why?
|
Dogs | 1 | 2008 | 3822 | 0.010 |
Why?
|
Systole | 1 | 2006 | 935 | 0.010 |
Why?
|
Proteins | 1 | 2017 | 5996 | 0.010 |
Why?
|
Gastrointestinal Tract | 1 | 2008 | 834 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2017 | 14445 | 0.010 |
Why?
|
Phenotype | 1 | 2019 | 16706 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2022 | 26284 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2018 | 15883 | 0.010 |
Why?
|
Pregnancy | 1 | 2021 | 30248 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2017 | 22321 | 0.010 |
Why?
|
Point-of-Care Systems | 1 | 2007 | 1217 | 0.010 |
Why?
|
Body Weight | 1 | 2008 | 4624 | 0.010 |
Why?
|
Rats, Sprague-Dawley | 1 | 2008 | 8102 | 0.010 |
Why?
|
Linear Models | 1 | 2007 | 5876 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2007 | 8528 | 0.010 |
Why?
|
Heart Rate | 1 | 2006 | 4202 | 0.010 |
Why?
|
Signal Transduction | 1 | 2017 | 23589 | 0.010 |
Why?
|
Rats | 1 | 2008 | 23704 | 0.010 |
Why?
|
Young Adult | 1 | 2017 | 59852 | 0.010 |
Why?
|
Retrospective Studies | 1 | 2019 | 81457 | 0.010 |
Why?
|
Mice | 1 | 2017 | 81792 | 0.010 |
Why?
|
Blood Pressure | 1 | 2006 | 8533 | 0.010 |
Why?
|
Adolescent | 1 | 2017 | 88781 | 0.000 |
Why?
|